Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 2c

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q3 EPS of ($0.70), $0.02 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Five Below ’priced for perfection’, says Loop Capital
• BXP Inc. (BXP) PT Raised to $70 at UBS as Earnings Outlook Accelerates